## 1 Manuscript Title – Population-level Impact of HPV Vaccination On the Incidence of

- 2 Genital Warts in Sweden
- 3 Authors: Ana Martina Astorga Alsina<sup>\*1</sup>, Eva Herweijer<sup>2</sup>, Jiayao Lei<sup>\*1,3</sup>

## 4 Affliliations:

- <sup>5</sup> <sup>1</sup> Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Nobels väg
- 6 12A, SE-17177 Stockholm, Sweden
- 7 <sup>2</sup> Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
- 8 <sup>3</sup> Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Alfred
- 9 Nobels Allé 8, SE-141 52 Stockholm, Sweden

## 10 Abstract

- 11 Background: Sweden introduced HPV vaccination in 2006, administered through
- 12 opportunistic, subsidized, catch-up and school-based programs. Notably, genital warts (GW)
- 13 are the first observable clinical outcome following infection by HPV-6/11, targeted by
- 14 vaccination. We aim to gain knowledge of the population incidence of GW in Sweden and
- 15 evaluate its change throughout vaccination programs.
- 16 Methods: This ecological study used Swedish registers to obtain national population data and
- 17 cases of genital warts from 2006-2018 in men and women aged 15-44. We used Poisson
- 18 models to evaluate GW incidence change after vaccination in reference to a pre-vaccination
- 19 period, stratified by age and sex. As well as, to estimate incidence change of GW in birth
- 20 cohorts eligible for different vaccination programs compared to a pre-vaccination cohort.
- 21 Finally, we estimated GW cases averted in each vaccinated cohort.
- 22 **Results:** The incidence of GW decreased during periods following HPV vaccination. In
- 23 2016-2018, over a decade after vaccination availability, incidence decreased by 89% (95% CI
- 24 83-93), 73% (95% CI 71-75), 50% (95% CI 43-56) and 20% (95% CI 10-28) in women aged
- 25 15-19, 20-24, 25-29 and 30-34, respectively. A similar reduction was observable in men,
- although of lesser magnitude. We estimated 18,890 and 12,343 GW cases averted among
- 27 vaccinated cohorts of women and men, respectively.
- 28 Conclusions: We report on population-level decreases of GW incidence in women and men
- 29 following increased vaccination coverage. Cohorts eligible for school-based vaccination
- 30 recorded the largest decrease in GW incidence in Sweden to date. For the period under study,
- decreases among men could be attributed to herd effects.
   NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 32 Introduction

33 In 2020, the World Health Organisation (WHO) proposed a global strategy to eliminate cervical cancer as a public health issue, aiming to achieve 90% vaccination coverage against 34 human papillomavirus (HPV) in girls by age 15 [1]. In Sweden, immunisation against HPV 35 was first offered in October 2006, with almost exclusive administration of the quadrivalent 36 37 vaccine (i.e. covering HPV-6/11/16/18) until 2019 [2-4]. Initially, vaccination was opportunistic and required an out-of-pocket fee but was subsidised from May 2007 38 (supplementary Figure S1 & Table S1) [2]. National coverage remained low until vaccination 39 delivery changed to a structured school-based program in 2012, accompanied with a catch-up 40 program, and no out-of-pocket fee [3-4]. Since then, coverage of at least one dose increased to 41 80% and 60% for the school-based program cohorts and catch-up program cohorts, respectively 42 [6]. Later, in 2016, another catch-up opportunity came within the school-based program for 43 44 those under 18 [4]. Males were mostly excluded from national vaccination programs until the 45 extension of school-based vaccination in autumn 2020 [5].

46 Monitoring the impact of changing HPV vaccination coverage on cervical cancer 47 incidence can be challenging due to the prolonged latency period. Clinical outcomes of HPV that precede cancer, such as cervical lesions or genital warts (GW), are thus useful to monitor 48 49 potential impact at an earlier stage. 90% of GW cases are associated with HPV-6/11, covered by quadrivalent and nonavalent vaccines [7]. They may develop as early as 2-3 months from 50 51 the point of infection and are widely reported by healthcare registers in Sweden [7]. As a result, they serve as the first observable disease measure to assess early effectiveness of HPV vaccines 52 53 [8,9].

54 Several countries have reported reductions of GW incidence following HPV 55 vaccination program implementation [10–13]. However, in Sweden, GW are not included in 56 the mandatory surveillance of infectious diseases, and incidence has only been reported up until 57 2012 [3,6,14,15]. Thus, to date, the school-based vaccination program change has not been 58 evaluated for its population impact on GW.

We aim to examine the incidence trend of GW from 2006 to 2018 among 15-44 year
old men and women in Sweden, in relation to subsequent national HPV vaccination programs.
The inclusion of men allows for exploration of possible protection via herd-effect since their
coverage during the study period is virtually zero. We also estimate cases of GW averted among
birth cohorts eligible for Sweden's sequential HPV vaccination programs.

64

## 65 Methods

66

## Study Population & Data Collection

67 Our study followed an ecological time-trend design, where GW time-varying disease 68 rates were retrospectively compared in a population geographically limited to Sweden. The 69 study's target population consists of men and women aged 15 to 44, registered in Sweden 70 between 2006 to 2018.

71 We collected aggregated Swedish population data from the Total Population Register (TPR), maintained and reported by Statistics Sweden. The TPR holds registration of all 72 73 individuals permanently residing in Sweden since 1968 [16]. We also obtained counts of GW cases through healthcare register data from the National Patient Register (NPR) using the ICD-74 75 10 code denoting an anogenital wart diagnosis (A63.0) [17], and from the Prescribed Drug Register (PDR) using ATC codes for podophyllotoxin (D06BB04) and imiquimod (D06BB10) 76 77 [18]. Non-pharmacological treatments used in persistent cases after first-line pharmacological 78 treatment were excluded.

79

### Vaccination Coverage

We defined exposure categorically based on HPV vaccination coverage at the 80 81 population-level, in relation to Sweden's sequential vaccination programs. Periods of pre- and post-vaccination were defined via coverage reported by the Public Health Agency of Sweden, 82 which refers to all those who have received at least one dose of a HPV vaccine [5]. We defined 83 the pre-vaccination period as 2006-2007 because vaccination was introduced late in 2006 and 84 85 coverage remained close to zero during this period (supplementary Figure S1). The postvaccination periods include 2008-2011, 2012-2015 and 2016-2018, which registered 86 87 sequentially increased coverage (i.e. specific to each birth cohort), of up to 34%, 55% and 84%, respectively [5]. 88

Subsequently, these categorical classifications were made based on birth cohort eligibility for each national program (supplementary Table S1 and Figure S2). Pre-vaccination birth cohorts include 1961-1985, who were not targeted by any national vaccination programs, and 1986-1988, who may have been vaccinated opportunistically but without subsidy (i.e. coverage does not exceed 10%) [5]. Meanwhile, post-vaccination birth cohorts include 1989-1992, who were part of the subsidised vaccination program, 1993-1998, who were eligible for

the subsidised vaccination program and the 2012 catch-up program, as well as 1999-2003, who
participated in the school-based vaccination program.

## 97 Genital Wart Cases

Cases of GW are considered a sufficiently specific outcome that allows measurement of vaccination effects as 90% of cases are ascribed to HPV-6/11, which are targeted by the quadrivalent vaccine in use during the study period [7, 19]. We included both first-occurring and subsequent cases of GW from any single individual, since no differentiation was made between these. A new case was included in the absence of any GW-related clinical or pharmaceutical registers in the 6 months prior. We pooled counts of GW cases, aggregated by sex, age-at-diagnosis, period of diagnosis and birth cohort.

## 105 Statistical Analyses

We report descriptive plots, a period analysis and a cohort analysis performed using 106 107 Stata (version 18). We first merged population and case data (see supplementary Section S1:Methods) [20]. Then, our descriptive analyses involved crude estimates for incidence rate 108 109 (IR) of GW, derived from the number of GW cases divided by the corresponding person-years 110 at risk. We plotted age-specific incidence by various calendar periods, and period-specific 111 incidence by age groups [21]. These were illustrated for women and men respectively. In the period analysis that followed, we estimated incidence rate ratios (IRR) and 95% confidence 112 113 intervals (CI) for post-vaccination periods using the pre-vaccination period (i.e. 2006-2007) as reference. To do so, we employed Poisson regression models with a categorical period variable 114 115 as the predictor and robust standard errors, stratifying by each age and sex category.

116 After this, we conducted a cohort analysis to estimate IRR with 95% CIs for each birth 117 cohort group eligible for subsequent vaccination programs using the youngest pre-vaccination 118 cohort, 1986-1988, as reference. We used a Poisson regression model with robust standard errors, and a categorical cohort variable as predictor. As covariates, we included age and period 119 120 as restricted cubic splines with 6 knots and 3 knots, respectively. We then estimated the amount 121 of GW cases averted with 95% CIs for each post-vaccination birth cohort group. This was done 122 by first estimating the number of GW cases in each vaccinated cohort using each cohort's 123 different estimated effects and size. Then, we compared this with the corresponding expected 124 number of GW cases when the cohort effect was forced to be the same as in the referent pre-125 vaccination cohort using the margin command in Stata [22]. The difference between estimated

and expected GW cases was considered as the number of GW cases averted through HPVvaccination.

Finally, we performed sensitivity analyses to evaluate robustness in our estimates. In the period analysis, we explored the sensitivity of our estimates to an adjustment for seasonal effects. This involved running the same model for each age and sex category with the inclusion of a categorical season variable as a covariate. In the cohort analysis, a negative binomial model was included to compare model sensitivity using the same predictors and covariates as the main model. Using this model, we again estimated IRR and subsequently, the number of cases averted.

135

## 136 **Results**

Our study included a total of 184,006 incident cases of GWs among 15-44 year old Swedish residents from 2006 to 2018, including 80,296 cases detected in women and 103,710 in men (Table 1). The study population accumulated a total of 23.64 million person-years from women and 24.83 million from men throughout the study period.

In the descriptive figures, we noticed a difference in age trends of GW incidence between women and men where the maximum IR among women in 2006-2007 is seen at age 21 (1178 cases per 100,000 person-years), while among men at 23 (1167 cases per 100,000) (Figure 1). Besides this, however, crude curves for GW cases by age-at-diagnosis appeared mostly similar among women and men, with 71% of cases occurring before 30 among women and 66% among men (Table 1).

Then, when inspecting crude IR over calendar time visually, we observed a declining
pattern of varying magnitude among those aged 15-19, 20-24 and 25-29 (Figure 2). This was
also reflected in the flattening of the age curve across period strata (Figure 1). Among women,
the decline appeared to begin from 2007/2008 while in men it appeared later around 2010
(Figure 2).

152 Similarly, through the Poisson model of the period analysis, we estimated the largest 153 and earliest decreases in IR of GW among women aged below 30. This was for each 154 consecutive period in reference to the pre-vaccination period (i.e. 2006-2007) (Figure 3, 155 supplementary Table S2). Among this group, we could clearly observe a pattern of increased 156 IR reductions in later time periods. Among 15-19 year olds, for example, IRR estimates showed

decreases of 10% (95% CI (-22)-33), 64% (95% CI 50-75) and 89% (95% CI 83-93) for 20082011, 2012-2015 and 2016-2018, respectively. Besides this, we could also observe a pattern of
decreased reductions with increased age. This difference is observed in the comparably smaller
estimates among 20-24 year olds of 12% (95% CI 5-19), 49% (95% CI 44-54) and 73% (95%
CI 71-75) for 2008-2011, 2012-2015 and 2016-2018, respectively. Meanwhile among 25-29
year olds we estimated this decrease at 12% (95% CI 0-23), 31% (95% CI 21-40) and 50%
(95% CI 43-56) for the same time periods, respectively.

Among women aged above 30, on the other hand, we observed stable IR over time compared to the reference pre-vaccination period (Figure 3, supplementary Table S2). Unlike women aged below 30, we generally didn't observe a consistent pattern of increasing IR reductions for later time periods in this age group. This could only be observed in women aged 30-34, whose estimates in 2012-2015 begin to show a decrease in IR of 10% (95% CI 0-19), and later 20% (95% CI 10-28) in 2016-2018. Estimates of women aged 40-44 in 2016-2018 showed the largest increases in GW IR at any period of 25% (95% CI 13-38).

171 When it comes to men, we observed comparable patterns to those among women, 172 including increased reductions of IR over time and at younger ages. Although, estimates of IR 173 decreases were lower than their female counterparts in those under 30, with the largest 174 estimated decreases among those aged 15-19 in 2012-2015 and 2016-2018 being 40% (95% 175 CI 1-64) and 79% (95% CI 64-88), respectively (Figure 3, supplementary Table S2). Meanwhile estimates of IR increase among men over 30 were higher compared to women, 176 177 reaching 55% (95% CI 36-78) among 40-44 year olds in 2016-2018. We also generally observed wider CIs among men compared to women. 178

179

# Comparison Of Birth Cohorts

Cohort analyses showed significant changes in incidence of GW in post-vaccination birth cohorts compared to the reference birth cohort, 1986-1988 (Table 2). With the Poisson model, we estimated a decrease in incidence of 23% (95% CI 18-27), 62% (95% CI 58-65) and 93% (95% CI 90-95) in birth cohorts of women eligible for subsidised, catch-up and schoolbased vaccination, respectively. Meanwhile, in male birth cohorts that corresponded to cohorts of women eligible for vaccination, we saw similar decreases in risk, of 19% (95% CI15-22), 56% (95% CI 52-59) and 85% (95% CI 81-88), respectively.

Using IR of the reference cohort as a counterfactual scenario allowed us to estimate 187 cases of GW averted in each birth cohort. This way, we estimated 31,233 cases of GW averted 188 189 in cohorts that were eligible for any structured national HPV vaccination program, compared 190 to what would have been expected if the cohort effect had been the same as the reference pre-191 vaccination cohort's. This included 18,890 cases among women and 12,343 cases among men 192 (Table 2). The largest number of cases averted were in cohorts 1993-1998 followed by 1989-193 1992 and then 1999-2003. This is true in both sexes while the estimated number of cases 194 averted is lower in men, and this difference is larger in younger cohorts.

## 195 Sensitivity Analysis

196 Sensitivity analyses showed robustness of our estimates to modified assumptions. In the period analysis, our estimates were comparable after adjustment for seasonality 197 198 (supplementary Table S3): changes in the magnitude of associations were negligible, with those among men aged 15-19 being the largest, while CIs were comparable. In the cohort analysis, 199 200 model-sensitivity analysis showed robustness to specification error, with the results produced 201 by the negative binomial model being very similar to the main analysis: IRRs estimated from 202 the negative binomial model were generally slightly larger, and consequently led to larger 203 estimates of cases averted (supplementary Table S4), while CIs were comparable.

204

#### 205 Discussion

206 We demonstrate a decreased incidence of GW after the introduction of HPV vaccination, with a larger decrease over time as vaccination coverage increased. This trend is 207 208 clearly observed in women below the age of 30, who were eligible for a structured vaccination program. This age group also displays a clear trend of reduced decreases in IR with older age, 209 210 correlating with a decrease in coverage with increased age. In contrast, the estimated IR for 211 women aged over 30 (i.e. born before 1989) generally remained approximately stable. This 212 population would generally not have had access to subsidised vaccination, and coverage would 213 be vulnerable to disparities influencing opportunistic access. An exception is observed among 214 those aged 30-34 who have a decreased IR after 2012, likely due to some coverage from the opportunistic vaccination period prior to subsidisation 215

While IR trends over the study period observed in men resembled those observed in 216 217 women, some differences allude to their differential protection. IRR estimates among men were 218 generally more positive, indicating lesser magnitude decreases and higher magnitude increases 219 in incidence. This alludes to a lower protective effect among men, in-line with their general 220 lack of direct protection against HPV. Among those under 30, estimates showed no significant 221 trends until 2012-2015. This indicates a lag in effect in this population compared to women. 222 Men were only included in a national HPV vaccination program in Sweden from autumn 2020. 223 Thus, if these trends were attributed to protection via a vaccination program, it could only be 224 indirect protection via herd effect.

225 Additionally, we report the lowest estimated IRR in birth cohort group 1999-2003. Despite this, most cases averted corresponded to birth cohort, 1993-1998, who were likely 226 protected via a mix of the opportunistic and catch-up program (supplementary Table S1). In 227 228 this group, vaccination coverage is relatively high, and they are included in the study 229 throughout peak infection ages, thereby accounting for many cases averted. While coverage is 230 also high for cohorts 1999-2003, the study period only included them before the age of 231 maximum incidence of GW (supplementary Figure S3). Similarly, even though coverage is 232 lower in cohorts born 1989-1992, their inclusion in the study during a wide age range of high 233 incidence of GW resulted in many averted cases estimated.

234 Overall, our results indicated that GW incidence sees a higher decrease over time and 235 lower decrease with increased age during the study period. This could be attributed to higher coverage and inclusion of younger cohorts, who may have also been vaccinated at an earlier 236 237 age. We also indicate a possible increased herd effect in men over time. These observations are reliant on GW diagnostics remaining constant during the study period, and do not consider 238 239 differences in protection from differential vaccine doses. While it is difficult to definitively 240 differentiate between the effect of distinct vaccination programs, the introduction of 241 subsidisation and structured delivery in school-settings likely facilitated convenience for vaccination uptake and resulted in the observable increase in vaccination coverage; 242 consequently, a comparable potential impact on incidence of GW seems plausible. 243

244 Our results corroborate with existing reports of GW trends in earlier time periods following HPV vaccination in the Swedish population. This includes a decrease in IR of GW 245 246 among women aged 15-24 from 2008, and among men from 2010-2012 [6]. However, while previous studies state no change in GW IR for women above 30 years of age, we report 247

decreases in women aged 30-34 from 2012 onwards and in men from 2016 [6]. This finding isascribed to our study's prolonged follow-up since vaccine introduction.

250 Furthermore, our results align with literature from other countries concerning impact of 251 vaccination programs on incidence of GW. Comparable estimates from a Danish population 252 registry study of GW incidence 5 years after vaccine implementation found decreases of 55% 253 among women aged 12-35, and 37% among men aged 12-29 [10]. Similarly, an Australian 254 serial cross-sectional study estimated a 68% reduction in GW diagnoses among women aged 255 above 15 and a 49% reduction among men of the same age during the initial girls-only 256 vaccination period [12]. Much like our estimates, they report smaller decreases of GW 257 incidence with increasing age. A Canadian study evaluating the first cohorts eligible for school-258 based vaccination estimated a GW incidence decline of 72% in women 16-18 years of age and 51% in men of the same age [11]. Meanwhile, summary estimates from a meta-analysis 259 260 indicated faster and more significant decreases of GW in women aged 15-24 in high coverage 261 contexts (>50%), reinforcing the relationship between GW IR change and the coverage 262 achieved by vaccination programs [13]. Among women aged 25-29 and men aged 15-24, their 263 estimates were only significant in high coverage settings where indirect protection may have 264 had an increased effect. This aligns with our estimates. Meanwhile, among men aged 25-29, 265 the meta-analysis estimated significant effects in high coverage contexts over 5 years post-266 vaccination like our estimates for the same group, 6 years post-vaccination [13].

267 There are some limitations in our study. Firstly, GW cases were obtained only for men who are first-degree relatives of the female population, resulting in an underestimation of the 268 269 true IR when using the person-time of the total population. However, given that our study 270 covers an estimated 96% of the male population in Sweden, we expect this bias to be small. We also cannot account for any HPV vaccinations received before immigrating to Sweden, 271 272 which may result in an underestimation of coverage. Depending on the overall background risk 273 of GW among immigrants, this could contribute to an over- or underestimation of the impact 274 on GW. Furthermore, some GW cases may be erroneously classified as such through the 275 prescription of podophyllotoxin and imiquimod for other conditions. The most common of these conditions, namely superficial basal cell carcinoma and actinic keratoses, are mostly 276 277 associated with ages 40 or above [23], minimising bias within the age range of interest. Molluscum contagosium, however, is often found in young, sexually active adults and could 278 279 lead to an overestimate of GW incidence in our population [24, 25]. This could introduce bias 280 if cases of molluscum contagosium were differential over the study period. Similarly, lack of

health-seeking for GW could lead to an underestimation of cases, although this is not expected
to be differential over time. Finally, regression of GW cases before identification by either NPR
or PDR could contribute to an underestimation of cases. However, GW may often recur and
presumably be identified in the national healthcare registers eventually [7].

Furthermore, the ecological time-trend design is prone to ecological fallacy and confounding from time-varying factors. Crucially, our interpretations on impact of vaccination programs are limited to the group-level rather than on any individual. Meanwhile, confounding factors including changing sexual or healthcare-seeking behavior, may also relate to components of the vaccination program that are not vaccination itself, such as increased public campaigns or education of school-personnel. This confounding effect can be partially explored by comparing other STI trends as negative controls.

292 Nonetheless, we benefit from a series of important strengths. GW cases from the 293 nationwide registers were obtained with near complete coverage of men and women registered 294 in Sweden between 2006-2018. These registers constitute valid and reliable sources for the 295 outcome selected that allow for high statistical power and minimised risk of selection bias. 296 Meanwhile the ecological design allowed for estimates on the total impact of the HPV 297 vaccination program, including both direct and indirect protective effects of the HPV vaccine. 298 This allowed us to report on highly relevant measures at the population level, with significant 299 relevance to the surveillance of vaccination program performance.

300 Our study provides national-level estimates of the incidence of GW in Sweden 12 301 years after introduction of HPV vaccination, highlighting trends related to different vaccination delivery approaches. These findings should be generalisable to most settings with 302 303 similarly structured vaccination programs, achieving comparable coverage rates. Our results 304 fall in-line with recommendations from the WHO and the European Centre for Disease 305 Prevention and Control, which advocate for the increased effectiveness of school-based HPV 306 vaccination at younger ages. By demonstrating the differential population-level impact of 307 various vaccination programs, our findings are crucial for informing policy- and decisionmakers on optimizing national immunization programs. Continuous monitoring of the 308 309 programs and evaluation of GW incidence trends are essential, possibly exploring the potential for eliminating GW through HPV vaccination. 310

In conclusion, we demonstrate significant decreases of GWs among women under 30and, more recently, a comparably smaller but sizeable decrease among men through possible

- 313 herd effect. Cohorts eligible for subsidised national HPV vaccination programs are associated
- 314 with significantly lower incidence of GW, especially those vaccinated through the school-
- 315 based program. Ultimately, underscoring the importance of structured and targeted
- 316 vaccination strategies that minimise cost barriers and maximise convenience, to reduce HPV-
- 317 related disease outcomes.

## 318 Ethical considerations

- 319 This study was approved by the regional ethical review board in Stockholm (Dnr. 02-556,
- 320 2011/921-32, and 2023-06456-02), and concluded that informed consent from the study
- 321 subjects was not required.

## 322 Funding

- 323 This work was supported by the Swedish Research Council (Vetenskapsrådet) (No. 2023-
- 324 01809), the Swedish Research Council for Health, Working Life and Welfare (FORTE) (No.
- 325 2023-01221), and Karolinska Institutet Strategic Research Area in Epidemiology and
- 326 Biostatistics (JL). The funders have no role in considering the study or in the collection,
- 327 analysis, interpretation of data, writing of the report, or decision to submit the article for
- 328 publication.

## 329 Acknowledgements

- 330 We would like to acknowledge Prof. Pär Sparen for database establishment and valuable
- 331 discussion, Pouran Almstedt for data management, as well as Alexander Ploner for consistent
- 332 statistical support.
- 333 Conflicts of Interest
- None to declare.

## 335 Statement of Data Availability

- 336 Data not publicly available.
- 337
- 338
- 339
- 340
- 341

## 342 **References**

343

344	1.	World Health Organisation. Global strategy to accelerate the elimination of cervical
345		cancer as a public health problem. Available at:
346		https://www.who.int/publications/i/item/9789240014107. Accessed 1 July 2024.
347	2.	Tegnell A, Dillner J, Andrae B. Introduction of human papillomavirus (HPV)
348		vaccination in Sweden. Eurosurveillance. European Centre for Disease Prevention
349		and Control; 2009; 14(6):19119.
350	3.	Leval A, Herweijer E, Ploner A, et al. Quadrivalent Human Papillomavirus Vaccine
351		Effectiveness: A Swedish National Cohort Study. JNCI: Journal of the National
352		Cancer Institute. Oxford Academic; 2013; 105(7):469–474.
353	4.	Lei J, Ploner A, Elfström KM, et al. HPV Vaccination and the Risk of Invasive
354		Cervical Cancer. New England Journal of Medicine. Massachusetts Medical Society;
355		2020; 383(14):1340–1348.
356	5.	Folkhälsomyndigheten. Statistik om HPV-vaccinationer 2007–2017. Available at:
357		https://www.folkhalsomyndigheten.se/folkhalsorapportering-
358		statistik/statistikdatabaser-och-visualisering/vaccinationsstatistik/statistik-for-hpv-
359		vaccinationer/. Accessed 6 January 2024.
360	6.	Herweijer E, Ploner A, Sparén P. Substantially reduced incidence of genital warts in
361		women and men six years after HPV vaccine availability in Sweden. Vaccine; 2018;
362		36(15):1917–1920.
363	7.	Garland SM, Steben M, Sings HL, et al. Natural History of Genital Warts: Analysis of
364		the Placebo Arm of 2 Randomized Phase III Trials of a Quadrivalent Human
365		Papillomavirus (Types 6, 11, 16, and 18) Vaccine. J Infect Dis. Oxford Academic;
366		2009; 199(6):805–814.
367	8.	World Health Organisation. Report of the meeting on HPV Vaccine Coverage and
368		Impact Monitoring. Available at:
369		https://www.who.int/publications/i/item/WHO_IVB_10.05. Accessed 7 March 2024.
370	9.	Mariani L, Vici P, Suligoi B, Checcucci-Lisi G, Drury R. Early Direct and Indirect
371		Impact of Quadrivalent HPV (4HPV) Vaccine on Genital Warts: a Systematic Review.
372		Adv Ther. Springer Healthcare; 2015; 32(1):10–30.
373	10.	Bollerup S, Baldur-Felskov B, Blomberg M, Baandrup L, Dehlendorff C, Kjaer SK.
374		Significant Reduction in the Incidence of Genital Warts in Young Men 5 Years into

375		the Danish Human Papillomavirus Vaccination Program for Girls and Women. Sex
376		Transm Dis; 2016; 43(4):238–242.
377	11.	Righolt CH, Willows K, Kliewer E V., Mahmud SM. Incidence of anogenital warts
378		after the introduction of the quadrivalent HPV vaccine program in Manitoba, Canada.
379		PLoS One. PLOS; <b>2022</b> ; 17(4).
380	12.	Chow EPF, Carter A, Vickers T, et al. Effect on genital warts in Australian female and
381		heterosexual male individuals after introduction of the national human papillomavirus
382		gender-neutral vaccination programme: an analysis of national sentinel surveillance
383		data from 2004–18. Lancet Infect Dis. Elsevier; 2021; 21(12):1747–1756.
384	13.	Drolet M, Bénard É, Pérez N, et al. Population-level impact and herd effects
385		following the introduction of human papillomavirus vaccination programmes: updated
386		systematic review and meta-analysis. The Lancet. Elsevier; 2019; 394(10197):497-
387		509.
388	14.	Leval A, Herweijer E, Arnheim-Dahlström L, et al. Incidence of Genital Warts in
389		Sweden Before and After Quadrivalent Human Papillomavirus Vaccine Availability. J
390		Infect Dis. Oxford Academic; 2012; 206(6):860–866.
391	15.	Folkhälsomyndigheten. Notifiable Diseases [Internet]. 2023. Available from:
392		https://www.folkhalsomyndigheten.se/the-public-health-agency-of-
393		sweden/communicable-disease-control/surveillance-of-communicable-
394		diseases/notifiable-diseases/. Accessed 11 July 2024.
395	16.	Ludvigsson JF, Almqvist C, Bonamy AKE, et al. Registers of the Swedish total
396		population and their use in medical research. Eur J Epidemiol; <b>2016</b> ; 31(2):125–136.
397	17.	Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the
398		Swedish national inpatient register. BMC Public Health. BioMed Central; 2011;
399		11(450):1–16.
400	18.	Wettermark B, Hammar N, Fored CM, et al. The new Swedish Prescribed Drug
401		Registeropportunities for pharmacoepidemiological research and experience from
402		the first six months. Pharmacoepidemiol Drug Saf; 2007; 16(7):726–735.
403	19.	Lipsitch M, Jha A, Simonsen L. Observational studies and the difficult quest for
404		causality: lessons from vaccine effectiveness and impact studies. Int J Epidemiol.
405		Oxford Academic; 2016; 45(6):2060–2074.
406	20.	Rutherford MJ, Lambert PC, Thmpson JR. Ge-period-ohort modeling. The Stata
407		Journal. 2010; 10(4):606-627.

408	21. Carstensen B. Age-period-cohort models for the Lexis diagram. Stat Med. 2007;
409	26(15):3018–3045.
410	22. Falcaro M, Newson RB, Sasieni P. Stata tip 146: Using margins after a Poisson
411	regression model to estimate the number of events prevented by an intervention. Stata
412	Journal. SAGE Publications Inc.; 2022; 22(2):460-464.
413	23. Kappelin J, Green AC, Ingvar Å, Ahnlide I, Nielsen K. Incidence and trends of basal
414	cell carcinoma in Sweden: a population-based registry study. British Journal of
415	Dermatology. Oxford Academic; 2022; 186(6):963–969.
416	24. Hebert AA, Bhatia N, Rosso JQ Del. Molluscum Contagiosum: Epidemiology,
417	Considerations, Treatment Options, and Therapeutic Gaps. J Clin Aesthet Dermatol.
418	Matrix Medical Communications; 2023; 16(8 Suppl 1):S4.
419	25. Edwards S, Boffa MJ, Janier M, et al. 2020 European guideline on the management of
420	genital molluscum contagiosum. J Eur Acad Dermatol Venereol; 2021; 35(1):17-26.

# Tables & Figures

Population-level Impact of HPV Vaccination On the Incidence of Genital Warts in Sweden

September 19, 2024

	Men			Women				
	Genital Warts n=103,710		<b>Person-Years</b> n=24.83 million		<b>Genital Warts</b> n=80,296		<b>Person-Years</b> n=23.64 million	
	Cases	%	Millions	%	Cases	%	Millions	%
Age								
15-19	6,198	5.98	3.9	15.66	13,655	17.01	3.6	15.34
20-24	31,570	30.44	4.2	16.80	25,955	32.32	3.9	16.68
25-29	30,469	29.38	4.2	17.08	17,394	21.66	4.0	17.06
30-34	17,717	17.08	4.1	16.49	10,084	12.56	3.9	16.51
35-39	10,588	10.21	4.1	16.65	6,990	8.71	4.0	16.83
40-44	7,168	6.91	4.3	17.33	6,218	7.74	4.2	17.58
Calendar Year								
2006-2007	16,993	16.39	3.7	14.97	16,165	20.13	3.6	15.05
2008-2011	37,862	36.51	7.5	30.39	31,319	39.00	7.2	30.55
2012-2015	31,121	30.01	7.6	30.71	21,334	26.57	7.3	30.75
2016-2018	17,734	17.10	5.9	23.93	11,478	14.29	5.6	23.65
Birth Cohort								
1961-1985	60,467	58.30	15.2	61.11	39,396	49.06	14.5	61.54
1986-1988	18,911	18.23	2.6	10.53	16,072	20.02	2.5	10.59
1989-1992	18,395	17.74	3.5	14.14	17,932	22.33	3.3	14.05
1993-1998	5,786	5.58	2.8	11.35	6,688	8.33	2.6	11.04
1999-2003	151	0.15	0.7	2.87	208	0.26	0.7	2.78

Table 1: Sex-specific genital warts cases and person-time per categories of age, period, and cohort

#### Women



Figure 1: Age-trend of genital warts incidence rates among women and men, stratified by period





Figure 2: Incidence rates of genital warts among women and men between 2006 and 2018, stratified by age group. Dashed vertical line at 2008, denoting start of post-vaccination period, and at 2012, denoting start of school-based vaccination period



Figure 3: Age-specific incidence rate ratio of genital warts cases for post-vaccination time periods in reference to pre-vaccination (i.e. 2006-2007), stratified by sex

Birth Cohort	Vaccination Program(s)	IRR (95% CI)	Cases (95% CI)		
		Women			
1961-1985	Pre-vaccination	1.02 (0.98 - 1.07)	-		
1989-1992	Subsidised	0.77 (0.73 - 0.82)	5,232 (3,970 - 6,494)		
1993-1998	Catch-up	0.38 (0.35 - 0.42)	10,925 (9,675 - 12,175)		
1999-2003	School-based	0.07 (0.05 - 0.10)	2,733 (2,347 - 3,119)		
			Men		
1961-1985	n/a	1.13 (1.09 - 1.18)	-		
1989-1992	n/a	0.81 (0.78 - 0.85)	4,236 (3,288 - 5,184)		
1993-1998	n/a	0.44 (0.41 - 0.48)	7,248 (6,525 - 7,970)		
1999-2003	n/a	0.15 (0.12 - 0.19)	859 (755 - 964)		

Table 2: Incidence Rate Ratio (IRR) of genital warts and estimated number of cases averted per birth cohort

\* Reference corresponds to birth cohort 1986-1988.